我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
尚未招募
1
50.0%
终止
暂无批准数据
- Valerio Therapeutics signed a binding offer to acquire Etherna Immunotherapies for a total enterprise value of €30 million, combining complementary RNA platform technologies. - The merger pairs Valerio's single-domain antibody targeting and conjugation technologies with Etherna's mRNA and customizable lipid nanoparticle (cLNP) capabilities plus GMP manufacturing. - The combined entity aims to advance at least two immunological programs through IND-enabling studies and into the clinic within 18 to 24 months, led by an in vivo CAR-T approach targeting pathological B- and T-cells. - The transaction is supported by existing Valerio shareholders with secured financing and voting commitments representing over 70% of voting rights, with a six-week exclusivity period to finalize documentation.
